Showing results (121-130 of 186) with videos related to

Sort By:
Pageof 19
Cancer|November 25, 2022
Clinical effects and emerging issues of atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma from Japanese real-world practiceMiyuki Nakagawa, Masanori Inoue, Sadahisa Ogasawara, et al.
Open Forum Infectious Diseases|May 25, 2019
Trends and Efficacy of Interferon-Free Anti-hepatitis C Virus Therapy in the Region of High Prevalence of Elderly Patients, Cirrhosis, and Hepatocellular Carcinoma: A Real-World, Nationwide, Multicenter Study of 10 688 Patients in JapanHidenori Toyoda, Masanori Atsukawa, Haruki Uojima, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|May 28, 2022
Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child-Pugh class A or B liver function in real-world clinical practiceTakaaki Tanaka, Atsushi Hiraoka, Toshifumi Tada, et al.
Liver Cancer|November 1, 2021
Posttreatment after Lenvatinib in Patients with Advanced Hepatocellular CarcinomaKeisuke Koroki, Naoya Kanogawa, Susumu Maruta, et al.
Journal of Gastroenterology|August 1, 2023
Efficacy and safety of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma patients with esophageal-gastric varicesFujimasa Tada, Atsushi Hiraoka, Toshifumi Tada, et al.
Cancer Medicine|January 22, 2025
Evaluation of Treatment Outcomes Using dNLR and GNRI in Combination Therapy With Atezolizumab and Bevacizumab for Hepatocellular CarcinomaAtsushi Naganuma, Satoru Kakizaki, Atsushi Hiraoka, et al.
Cancer Medicine|June 6, 2022
Does first-line treatment have prognostic impact for unresectable HCC?-Atezolizumab plus bevacizumab versus lenvatinibAtsushi Hiraoka, Takashi Kumada, Toshifumi Tada, et al.
Oncology|June 12, 2023
Lenvatinib as Second-Line Treatment after Atezolizumab plus Bevacizumab for Unresectable Hepatocellular Carcinoma: Clinical Results Show Importance of Hepatic Reserve FunctionAtsushi Hiraoka, Takashi Kumada, Toshifumi Tada, et al.
Oncology|August 8, 2023
Comparison between Atezolizumab Plus Bevacizumab and Lenvatinib for Hepatocellular Carcinoma in Patients with Child-Pugh Class B in Real-World Clinical SettingsHideko Ohama, Atsushi Hiraoka, Toshifumi Tada, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|June 12, 2023
Geriatric nutritional risk index as an easy-to-use assessment tool for nutritional status in hepatocellular carcinoma treated with atezolizumab plus bevacizumabAtsushi Hiraoka, Takashi Kumada, Toshifumi Tada, et al.
Pageof 19